Health News

Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.

Read more

Filed under: Pharmacy News
Tags: Drug, HIV, Pharmacy

Related posts

• University of Western Ontario receives FDA approval to begin SAV001 HIV trial (0)
  The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the United States Food and Drug Administration (FDA) to start human clinical trials. Read more [tags] Pharmacy News [/tags]
  
  
• UNITAID Concerned About Infant HIV Medication Shortage, Drug Company Says Supply Is Sufficient (0)
  Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet (... Read more [tags] Pharmacy News [/tags]
  
  
• U.S. Food And Drug Administration Approves Labeling Update For PREZISTA(R) To Include 96-Week Data In HIV-1 Infected Adult Patients (0)
  Tibotec Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs... Read more [tags] Pharmacy News [/tags]
  
  
• U-M scientists identify new reservoir for hidden HIV-infected cells that can serve as factory for new infections (0)
  University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new target for curing the disease so those infected with the virus may someday no longer rely on AIDS drugs for [...]
  
  
• Tibotec submits NDA for TMC278 anti-HIV compound to FDA (0)
  Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced [...]